PMID- 23288857
OWN - NLM
STAT- MEDLINE
DCOM- 20131226
LR  - 20220408
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Atherosclerotic disease in type 2 diabetes is associated with an increase in 
      sclerostin levels.
PG  - 1667-74
LID - 10.2337/dc12-1691 [doi]
AB  - OBJECTIVE: Wnt/beta-catenin signaling is related to the pathogenesis of several 
      diseases. Sclerostin is an inhibitor of Wnt/beta-catenin signaling. However, there 
      are few data regarding the sclerostin levels and vascular disease. Our aim was to 
      examine the relationship between serum sclerostin and atherosclerotic disease 
      (AD) in type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: We 
      performed a cross-sectional study including 78 T2DM patients (45.3% females, mean 
      age 59 +/- 5.7 years; 54.7% males, 57.4 +/- 6.7 years). RESULTS: Serum sclerostin 
      concentrations of T2DM patients in the AD group were significantly higher than in 
      the non-AD group (P = 0.006). For each increase of 1 pmol/L in sclerostin level, 
      there was a 4% increase of the risk of AD in T2DM patients. A concentration of >/= 
      42.3 pmol/L showed a sensitivity of 69% and a specificity of 54.8% to detect an 
      increased risk of AD. In males, sclerostin levels were higher in those with AD (P 
      = 0.04), abnormal intima-media thickness (IMT) (P = 0.004), carotid plaques (P < 
      0.001), and aortic calcification (P < 0.001). In females, higher levels of 
      sclerostin were related to abnormal IMT (P = 0.03) and aortic calcifications (P = 
      0.004). Homocysteine (beta = 0.319 [95% CI 0.561-2.586], P = 0.003) and IMT (beta = 
      0.330 [14.237-67.693], P = 0.003) were positively correlated with sclerostin. 
      CONCLUSIONS: Circulating sclerostin is increased in T2DM patients with 
      atherosclerotic lesions. Although the sample size of our study was small, these 
      data suggest that sclerostin levels could be a major modulator of Wnt signaling 
      in AD with implications in T2DM patients.
FAU - Morales-Santana, Sonia
AU  - Morales-Santana S
AD  - Bone Metabolic Unit, Red Tematica de Investigacion Cooperativa en Envejecimiento 
      y Fragilidad, Endocrinology Division, Hospital Universitario San Cecilio, 
      Granada, Spain.
FAU - Garcia-Fontana, Beatriz
AU  - Garcia-Fontana B
FAU - Garcia-Martin, Antonia
AU  - Garcia-Martin A
FAU - Rozas-Moreno, Pedro
AU  - Rozas-Moreno P
FAU - Garcia-Salcedo, Jose Antonio
AU  - Garcia-Salcedo JA
FAU - Reyes-Garcia, Rebeca
AU  - Reyes-Garcia R
FAU - Munoz-Torres, Manuel
AU  - Munoz-Torres M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130103
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Bone Morphogenetic Proteins)
RN  - 0 (Genetic Markers)
RN  - 0 (SOST protein, human)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing
MH  - Atherosclerosis/*blood
MH  - Bone Morphogenetic Proteins/*blood
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Female
MH  - Genetic Markers
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
PMC - PMC3661830
EDAT- 2013/01/05 06:00
MHDA- 2013/12/27 06:00
PMCR- 2014/06/01
CRDT- 2013/01/05 06:00
PHST- 2013/01/05 06:00 [entrez]
PHST- 2013/01/05 06:00 [pubmed]
PHST- 2013/12/27 06:00 [medline]
PHST- 2014/06/01 00:00 [pmc-release]
AID - dc12-1691 [pii]
AID - 1691 [pii]
AID - 10.2337/dc12-1691 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):1667-74. doi: 10.2337/dc12-1691. Epub 2013 Jan 3.